Literature DB >> 16305384

Relevance of multidrug resistance proteins on the clinical efficacy of cancer therapy.

V Merino1, N V Jiménez-Torres, M Merino-Sanjuán.   

Abstract

Variations in drug uptake and efflux, as well as changes in intracellular drug entrapment and distribution may represent important resistance mechanisms to cancer therapy. A variety of ATP binding cassette transporters (ABC) localised in multiple cell membranes is implied in those phenomena, representing a mechanism of protection of cells against xenobiotics. Many cancer cell lines over express some ABC transporters, especially p-glycoprotein, MRP1 and BCRP. This over expression is related to worse cancer treatment outcome and, in some cases, reduced overall survival of cancer patients. This paper reviews the location and physiological role of the three transporters mentioned and also describes the drugs that are substrates of these proteins. The usefulness of animal and cellular models to evaluate the role of these transporters on the uptake and efflux of anticancer drugs is discussed. Finally, the results of preclinical and clinical studies about the utility of some inhibitors of these pumps, as well as the implications of polymorphism of ABC transporters on the efficacy and safety of anticancer therapeutics are reported.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16305384     DOI: 10.2174/1567201043334650

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  9 in total

Review 1.  Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

Authors:  Chung-Pu Wu; Anna Maria Calcagno; Suresh V Ambudkar
Journal:  Curr Mol Pharmacol       Date:  2008-06       Impact factor: 3.339

2.  Molecular evidence and functional expression of a novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug efflux.

Authors:  Pradeep K Karla; Dhananjay Pal; Tim Quinn; Ashim K Mitra
Journal:  Int J Pharm       Date:  2006-11-15       Impact factor: 5.875

3.  Expression of P-glycoprotein and metallothionein in gastrointestinal stromal tumor and leiomyosarcomas. Clinical implications.

Authors:  Sofia Pérez-Gutiérrez; Ricardo González-Cámpora; Joaquín Amérigo-Navarro; Antonio Beato-Moreno; María Sánchez-León; Jesús María Pareja Megía; Juan Antonio Virizuela-Echaburu; Antonio López-Beltrán
Journal:  Pathol Oncol Res       Date:  2007-10-07       Impact factor: 3.201

Review 4.  Mathematical modeling as a tool for planning anticancer therapy.

Authors:  Andrzej Swierniak; Marek Kimmel; Jaroslaw Smieja
Journal:  Eur J Pharmacol       Date:  2009-10-13       Impact factor: 4.432

Review 5.  Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?

Authors:  Richard Callaghan; Frederick Luk; Mary Bebawy
Journal:  Drug Metab Dispos       Date:  2014-02-03       Impact factor: 3.922

6.  Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA.

Authors:  Oleh Taratula; Andriy Kuzmov; Milin Shah; Olga B Garbuzenko; Tamara Minko
Journal:  J Control Release       Date:  2013-05-03       Impact factor: 9.776

7.  The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord.

Authors:  Jennifer N Dulin; Meredith L Moore; Raymond J Grill
Journal:  J Neurotrauma       Date:  2013-01-23       Impact factor: 5.269

Review 8.  The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development.

Authors:  Gaetano Romano
Journal:  Scientifica (Cairo)       Date:  2013-12-05

9.  Generating inhibitors of P-glycoprotein: where to, now?

Authors:  Emily Crowley; Christopher A McDevitt; Richard Callaghan
Journal:  Methods Mol Biol       Date:  2010
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.